Details of the $1.65 Billion All-Cash Acquisition
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in cash to expand its broader medicines portfolio [cite: 75].
Viatris announced on Thursday that it will pay $36.50 per share in cash for Pacira, marking an approximately 45% premium over the Wednesday closing price of $25.20 for the Brisbane, California-based firm [cite: 75].
Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in cash to expand its medicines portfolio.
The transaction is slated for formal completion by the end of the year [cite: 75].















